Biotech investing easy as ABC: Contractor agrees work for stock deal

By Gareth Macdonald contact

- Last updated on GMT

ABC to take stock in firm treating cancer with lasers and shells
ABC to take stock in firm treating cancer with lasers and shells

Related tags: Immune system, Oncology

ABC Laboratories has agreed to provide privately-owned cancer vaccine firm Immunophotonics with development services in exchange for company stock.

The Missouri-based contract research organisation (CRO) ABC has been helping develop Immunophotonics’ lead product inCVAX – a candidate vaccine for solid tumours - for several years in a services agreement.

The CRO’s decision to continue this work in exchange for stock reflects Immunophotonics’ confidence in ABC’s ability “to continue to provide the highest quality analytical support for our inCVAX project” ​according to the biotech's chief drug development officer, Joe Raker.

ABC CEO John Bucksath was similarly enthusiastic about the partnership; describing Immunophotonics’ approach to treating cancer as having “has great potential to help patients in need​.”

Cancer vaccine

Immunophotonics’ lead product is part of a two injection cancer treatment. The first shot is used to guide a fibre optic cable that targets a laser that heats the tumour, which prompts it to release antigens.

A second injection then delivers a glucosamine polymer - called N-dihydro-galacto-chitosan (GC)​ - that activates immune cells, exposing them to the tumour antigens thereby generating a tumour specific T-cell response.

The glucosamine polymer is also called Protectin, which is derived from a type of glucose called chitin found in crustacean shells.

inCVAX has already been examined in Phase II clinical trials in Peru and the Bahamas​.


ABC joins existing Immunophotonics backers Cultivation Capital, St. Louis Arch Angels, Billiken Angels and the Missouri Technology Corporation, which took part in a $2.48m (€2.2m) Series A financing round in January​.

At the time Immunophotonics said it would use the cash to fund trials in Latin America and the US.

ABC also holds stock in cancer drug firm Euclises Pharmaceuticals – which is developing COX-2 inhibitors - through an investment made last September last.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more